EA200701986A1 - Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера - Google Patents
Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамераInfo
- Publication number
- EA200701986A1 EA200701986A1 EA200701986A EA200701986A EA200701986A1 EA 200701986 A1 EA200701986 A1 EA 200701986A1 EA 200701986 A EA200701986 A EA 200701986A EA 200701986 A EA200701986 A EA 200701986A EA 200701986 A1 EA200701986 A1 EA 200701986A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mixture
- menthol
- surfactants
- peg
- poloxamer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится по меньшей мере к одной композиции для лечения повышенных уровней триглицеридов, включающей терапевтически эффективное количество фенофибрата или другого фибратсодержащего лекарственного вещества, находящегося в непосредственном контакте с ментолом или со смесью поверхностно-активных веществ, где ментол может быть ментолом или смесью ментола и поверхдостно-активных веществ и где смесь поверхностно-активных веществ может быть смесью полиэтиленгликоля и полоксамера, как например, ПЭГ (1000) и полоксамера (407). Изобретение также относится к способу лечения повышенных уровней триглицеридов у субъекта, включающему введение субъекту композиции, содержащей терапевтически эффективное количество фенофибрата или другого фибратсодержащего лекарственного вещества и ментола или смеси поверхностно-активных веществ, где фенофибрат или другое фибратсодержащее лекарственное вещество находится в непосредственном контакте с ментолом или со смесью поверхностно-активных веществ, где ментол может быть ментолом или смесью ментола и поверхностно-активных веществ, а смесь поверхностно-активных веществ может быть смесью полиэтиленгликоля и полоксамера, как например, ПЭГ (1000) и полоксамера (407).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66619205P | 2005-03-30 | 2005-03-30 | |
PCT/US2005/047676 WO2006107357A1 (en) | 2005-03-30 | 2005-12-29 | Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200701986A1 true EA200701986A1 (ru) | 2008-04-28 |
Family
ID=35058530
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200701750A EA200701750A1 (ru) | 2005-03-30 | 2005-07-18 | Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер |
EA200701986A EA200701986A1 (ru) | 2005-03-30 | 2005-12-29 | Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200701750A EA200701750A1 (ru) | 2005-03-30 | 2005-07-18 | Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060222706A1 (ru) |
EP (2) | EP1861084A1 (ru) |
JP (2) | JP2008505934A (ru) |
KR (2) | KR20070113289A (ru) |
CN (3) | CN101212962A (ru) |
AU (2) | AU2005330266A1 (ru) |
BR (2) | BRPI0520138A2 (ru) |
CA (2) | CA2601372A1 (ru) |
EA (2) | EA200701750A1 (ru) |
IL (2) | IL185734A0 (ru) |
MX (2) | MX2007011858A (ru) |
WO (2) | WO2006107316A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0415121A (pt) * | 2003-10-10 | 2006-11-28 | Lifecycle Pharma As | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida |
US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
US7658944B2 (en) * | 2003-10-10 | 2010-02-09 | Lifecycle Pharma A/S | Solid dosage form comprising a fibrate |
US7569612B1 (en) | 2006-08-21 | 2009-08-04 | Mutual Pharmaceutical Company, Inc. | Methods of use of fenofibric acid |
JP2013047282A (ja) * | 2006-08-31 | 2013-03-07 | Aska Pharmaceutical Co Ltd | フェノフィブラート含有組成物 |
JP5186159B2 (ja) * | 2006-08-31 | 2013-04-17 | あすか製薬株式会社 | フェノフィブラート含有組成物 |
US20110097414A1 (en) * | 2007-02-26 | 2011-04-28 | Sandal Roshan Lal | Pharmaceutical compositions comprising adsorbate of fenofibrate |
ES2855426T3 (es) * | 2008-09-17 | 2021-09-23 | Mylan Inc | Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen |
US8632846B2 (en) * | 2010-09-17 | 2014-01-21 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
WO2013114153A2 (en) * | 2011-12-14 | 2013-08-08 | Lts Lohmann Therapie-Systeme Ag | Wafer and capsule formulations with enhanced dissolution rates for fenofibrate |
WO2014091318A1 (en) | 2012-12-11 | 2014-06-19 | Lupin Atlantis Holdings, S.A. | Reduced dose pharmaceutical compositions of fenofibrate |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
FR2737121B1 (fr) * | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6814977B1 (en) * | 1998-12-18 | 2004-11-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6368622B2 (en) * | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
US6383517B1 (en) * | 1999-01-29 | 2002-05-07 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6719999B2 (en) * | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
FR2795961B1 (fr) * | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation |
DE60028754T2 (de) * | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
WO2001051089A1 (de) * | 2000-01-13 | 2001-07-19 | Merck Patent Gmbh | Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler |
TWI293877B (en) * | 2000-09-20 | 2008-03-01 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
CA2480377A1 (en) * | 2002-03-26 | 2003-10-09 | Teva Pharmaceutical Industries Ltd. | Drug microparticles |
US20040005339A1 (en) * | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
MXPA05008902A (es) * | 2003-02-20 | 2005-10-05 | Teva Pharma | Soluciones de drogas en mentol. |
US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
US20050096390A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
US7658944B2 (en) * | 2003-10-10 | 2010-02-09 | Lifecycle Pharma A/S | Solid dosage form comprising a fibrate |
US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
BRPI0415121A (pt) * | 2003-10-10 | 2006-11-28 | Lifecycle Pharma As | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida |
WO2006037348A1 (en) * | 2004-10-01 | 2006-04-13 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and a statin |
-
2005
- 2005-07-18 WO PCT/US2005/025440 patent/WO2006107316A1/en active Application Filing
- 2005-07-18 JP JP2007520594A patent/JP2008505934A/ja active Pending
- 2005-07-18 CA CA002601372A patent/CA2601372A1/en not_active Abandoned
- 2005-07-18 BR BRPI0520138-1A patent/BRPI0520138A2/pt not_active IP Right Cessation
- 2005-07-18 EA EA200701750A patent/EA200701750A1/ru unknown
- 2005-07-18 EP EP05776409A patent/EP1861084A1/en not_active Ceased
- 2005-07-18 KR KR1020077023606A patent/KR20070113289A/ko not_active Application Discontinuation
- 2005-07-18 CN CNA200580049321XA patent/CN101212962A/zh active Pending
- 2005-07-18 MX MX2007011858A patent/MX2007011858A/es not_active Application Discontinuation
- 2005-07-18 AU AU2005330266A patent/AU2005330266A1/en not_active Abandoned
- 2005-12-29 WO PCT/US2005/047676 patent/WO2006107357A1/en active Application Filing
- 2005-12-29 CN CNA2005800492984A patent/CN101217950A/zh active Pending
- 2005-12-29 BR BRPI0520167-5A patent/BRPI0520167A2/pt not_active IP Right Cessation
- 2005-12-29 MX MX2007012125A patent/MX2007012125A/es not_active Application Discontinuation
- 2005-12-29 EA EA200701986A patent/EA200701986A1/ru unknown
- 2005-12-29 KR KR1020077023605A patent/KR20070120990A/ko not_active Application Discontinuation
- 2005-12-29 EP EP05258102A patent/EP1707196A1/en not_active Withdrawn
- 2005-12-29 JP JP2008504020A patent/JP2008534584A/ja active Pending
- 2005-12-29 CA CA002601374A patent/CA2601374A1/en not_active Abandoned
- 2005-12-29 US US11/323,886 patent/US20060222706A1/en not_active Abandoned
- 2005-12-29 AU AU2005330320A patent/AU2005330320A1/en not_active Abandoned
-
2006
- 2006-02-13 CN CNA2006800102032A patent/CN101217951A/zh active Pending
-
2007
- 2007-09-05 IL IL185734A patent/IL185734A0/en unknown
- 2007-09-05 IL IL185735A patent/IL185735A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006107316A1 (en) | 2006-10-12 |
EP1707196A1 (en) | 2006-10-04 |
AU2005330266A1 (en) | 2006-10-12 |
KR20070120990A (ko) | 2007-12-26 |
CA2601372A1 (en) | 2006-10-12 |
BRPI0520138A2 (pt) | 2011-04-19 |
EA200701750A1 (ru) | 2008-02-28 |
IL185735A0 (en) | 2008-01-06 |
JP2008505934A (ja) | 2008-02-28 |
MX2007011858A (es) | 2008-03-25 |
US20060222706A1 (en) | 2006-10-05 |
WO2006107357A1 (en) | 2006-10-12 |
CN101217951A (zh) | 2008-07-09 |
EP1861084A1 (en) | 2007-12-05 |
CN101217950A (zh) | 2008-07-09 |
IL185734A0 (en) | 2008-01-06 |
CN101212962A (zh) | 2008-07-02 |
BRPI0520167A2 (pt) | 2009-04-22 |
JP2008534584A (ja) | 2008-08-28 |
AU2005330320A1 (en) | 2006-10-12 |
MX2007012125A (es) | 2007-12-07 |
CA2601374A1 (en) | 2006-10-12 |
KR20070113289A (ko) | 2007-11-28 |
WO2006107316A8 (en) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200701986A1 (ru) | Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера | |
EA200701751A1 (ru) | Улучшенные составы фенофибрата | |
UY27320A1 (es) | Nuevas composiciones farmacéuticas | |
ATE275967T1 (de) | Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie | |
BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
DE60318867D1 (de) | Lösung zur nagel-verwendung | |
EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
ATE544866T1 (de) | Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung | |
EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
DK1663194T3 (da) | Anvendelse af SAHA til behandling af mesotheliom | |
EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
AR057631A1 (es) | Composiciones y metodos para incrementar la sensibilidad a insulina | |
ATE257386T1 (de) | Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien | |
JO3598B1 (ar) | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني | |
EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
ATE413865T1 (de) | Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür | |
MA30768B1 (fr) | Methodes d'administration d'agents hypoglycemiques a longue duree d'action | |
TNSN07343A1 (fr) | Compositions ophtalmologiques et leur mode d'utilisation | |
PE20061077A1 (es) | Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina | |
AR003589A1 (es) | Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido. | |
MX9400800A (es) | Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion. | |
EE05124B1 (et) | Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine | |
AR044660A1 (es) | Composiciones farmaceuticas de atorvastatina | |
EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида |